![conference banner](/images/conference-banner.jpeg)
Abstract
Depression is a major cause of worldwide disability. Although its etiology is unclear, for over sixty years the study of its pathophysiology has focused mainly on serotonin (5-HT) and serotonergic neurotransmission. Generally, the study of the pathophysiological processes underpinning depression have led to the appreciation of its complexity, although such study continues to support the role of 5-HT in this disorder.
The aim of this review is to briefly summarize the available findings on 5-HT and depression, with a special focus on alterations in tryptophan (TRP) metabolism that can shift from 5-HT synthesis towards other, potentially neurotoxic, compounds, such as the tryptophan catabolite, quinolinic acid.
The evidence that the TRP shunt may be promoted by stress hormones and proinflammatory cytokines strongly supports the notion that depression should now be considered a systemic disorder that can be triggered by different factors that ultimately target the 5-HT system in vulnerable individuals. In addition, such intriguing findings suggest biochemical targets for novel treatment options in depression.
Keywords: Depression, serotonin, biological markers, tryptophan, tryptophan shunt, kynurenine.
Current Pharmaceutical Design
Title:Depression, Serotonin and Tryptophan
Volume: 22 Issue: 8
Author(s): Liliana Dell’Osso, Claudia Carmassi, Federico Mucci and Donatella Marazziti
Affiliation:
Keywords: Depression, serotonin, biological markers, tryptophan, tryptophan shunt, kynurenine.
Abstract: Depression is a major cause of worldwide disability. Although its etiology is unclear, for over sixty years the study of its pathophysiology has focused mainly on serotonin (5-HT) and serotonergic neurotransmission. Generally, the study of the pathophysiological processes underpinning depression have led to the appreciation of its complexity, although such study continues to support the role of 5-HT in this disorder.
The aim of this review is to briefly summarize the available findings on 5-HT and depression, with a special focus on alterations in tryptophan (TRP) metabolism that can shift from 5-HT synthesis towards other, potentially neurotoxic, compounds, such as the tryptophan catabolite, quinolinic acid.
The evidence that the TRP shunt may be promoted by stress hormones and proinflammatory cytokines strongly supports the notion that depression should now be considered a systemic disorder that can be triggered by different factors that ultimately target the 5-HT system in vulnerable individuals. In addition, such intriguing findings suggest biochemical targets for novel treatment options in depression.
Export Options
About this article
Cite this article as:
Dell’Osso Liliana, Carmassi Claudia, Mucci Federico and Marazziti Donatella, Depression, Serotonin and Tryptophan, Current Pharmaceutical Design 2016; 22 (8) . https://dx.doi.org/10.2174/1381612822666151214104826
DOI https://dx.doi.org/10.2174/1381612822666151214104826 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Economic Evaluation in Paediatric Practice: Examples from Cardiac Critical Care
Current Pediatric Reviews Flavonoids, Vascular Function and Cardiovascular Protection
Current Pharmaceutical Design Significance of Pharmacogenetics and Pharmacogenomics Research in Current Medical Practice
Current Drug Metabolism Janus Kinase Inhibition with Tofacitinib: Changing the Face of Inflammatory Bowel Disease Treatment
Current Drug Targets The Two fACEs of the Tissue Renin-Angiotensin Systems: Implication in Cardiovascular Diseases
Current Pharmaceutical Design Role of Translocator Protein in Renal Ischemia Reperfusion, Renal Preservation and Acute Kidney Injury
Current Molecular Medicine An In-Silico Investigation of Anti-Chagas Phytochemicals
Current Clinical Pharmacology The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia
Current Topics in Medicinal Chemistry Lipid Alterations in the Earliest Clinically Recognizable Stage of Alzheimers Disease: Implication of the Role of Lipids in the Pathogenesis of Alzheimers Disease
Current Alzheimer Research Atherogenesis in Renal Patients: A Model of Vascular Disease?
Current Vascular Pharmacology Predictive In Silico Studies of Human 5-hydroxytryptamine Receptor Subtype 2B (5-HT2B) and Valvular Heart Disease
Current Topics in Medicinal Chemistry IP6 (Inositol Hexaphosphate) as a Signaling Molecule
Current Signal Transduction Therapy Blood Serum Atherogenicity and Coronary Artery Calcification
Current Pharmaceutical Design Neuromodulation of the Perinatal Respiratory Network
Current Neuropharmacology Morphology of Atherosclerotic Plaque: Its Feature by Imaging Study
Current Pharmaceutical Design The Predictive Role for ST2 in Patients with Acute Coronary Syndromes and Heart Failure
Current Medicinal Chemistry Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets The Role of Statins in Preventing the Progression of Congestive Heart Failure in Patients with Metabolic Syndrome
Current Pharmaceutical Design Hypoglycemia and Cardiac Arrhythmia; Mechanisms, Evidence Base a nd Current Recommendations
Current Diabetes Reviews Targeting Nitrosative Stress for Neurovascular Protection: New Implications in Brain Diseases
Current Drug Targets